Abstract-Atherosclerotic vascular disease is driven by chronic inflammation involving both innate and adaptive immune responses. Dendritic cells (DCs) are found in healthy arteries and accumulate in atherosclerotic lesions and engage in diverse pathogenic and protective mechanisms during atherogenesis. DCs contribute to early foam cell formation, regulate lipid metabolism, and control pro-and antiatherosclerotic T-cell responses by multifarious mechanisms. We, here, review the roles of DCs and plasmacytoid DCs in experimental models of atherosclerosis and the approaches to target DCs in therapeutic vaccination strategies. We, furthermore, discuss the evidence of the potential function of DCs in human atherosclerosis, and dissect the efforts to harness DC subsets as biomarkers of disease. Finally, we discuss necessary future steps that will help to understand the specific contribution of bona fide DCs in atherosclerosis to move toward novel therapeutic approaches.
A therosclerotic vascular disease remains the number one cause of death and morbidity in the Western world. It is now well established that atherosclerosis is a chronic inflammatory disease of the vessel wall. Besides macrophages, also other immune cells, namely dendritic cells (DCs) and T cells, can be found within atherosclerotic lesions and contribute to atherogenesis.
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In general, DCs have functionally been ascribed to play the main role in initiating antigen-specific adaptive immune responses and maintaining tolerance to self-antigens, whereas macrophages excel in phagocytotic processes. The distinction between DCs and macrophages, however, is much debated, in particular because of their partially overlapping phenotypes and functions. In previous studies, mostly promiscuous surface markers were used to discriminate these populations, and DCs were often defined as CD11c + major histocompatibility complex (MHCII) + 
CD11b
+ cells referred to as macrophages. Because of the paucity of studies clearly discriminating DCs and macrophages (see below) and their functional plasticity, the interpretation of these findings and published literature and a clear attribution to the cell type in atherosclerosis may, therefore, often be difficult.
Given these limitations, this review provides an overview about the role of cells ascribed to be DCs in atherosclerosis in mice and humans (Figure) , stating the markers used to identify these, and discusses necessary future steps that will help to understand the specific contribution of bona fide DCs in atherosclerosis to move toward novel therapeutic approaches.
Defining DCs
Recently, efforts have been undertaken to unequivocally define DCs and differentiate these from macrophages, taking the ontogeny, phenotype and transcriptional profile into account. [6] [7] [8] [9] [10] On the basis of these considerations, DCs in mice were proposed to be classified as a separate lineage of mononuclear phagocytes that arises from progenitors that are distinct from precursors of monocytes/macrophages. In the bone marrow common monocyte-DC precursors (MDPs) either give rise to monocyte progenitors restricted to monocytes and their descendants or commit toward DC precursors. Common DC precursors differentiate into plasmacytoid DCs (pDCs) in bone marrow, or can give rise to pre-DCs, which exit the bone marrow, circulate in blood and subsequently develop into classical DCs (cDCs). It should be noted that the exact 3 and Xcr1, and to require the transcription factors BATF3, IRF8, Id2 for their development, whereas the differentiation of CD11b + cDCs is controlled by RELB, RBPJ and IRF4. The transcription factor E2-2/Tcf4 is an essential regulator of pDC development. [6] [7] [8] [9] [10] [11] [12] Both cDCs and pDCs depend on the growth factor fms-like tyrosine kinase 3 ligand (Flt3L), and Flt3L-dependence can serve as a surrogate marker for common DC precursor origin. 6, 10 In contrast, macrophage colony-stimulating factor 1 receptor + monocytes that circulate in blood and enter tissues under inflammatory conditions, give rise to macrophages and monocyte-derived DCs. It is currently unclear if monocyte-derived DCs and macrophages constitute two distinct lineages, or if they are instead highly plastic cells that acquire different functional modules in response to microenvironmental cues 10 (Table 1 14 Similar to mice, DCs can be detected in the arterial intima of healthy young individuals, 32 and increased numbers of DCs are found in atherosclerotic lesions 29 using unspecific markers, such as S100, CD1a, or fascin. However, a detailed analysis of the different DC subsets is still lacking. DCs are mainly found in the plaque shoulder and rupture-prone regions, as well as in marginal parts of the plaque core. 23, 29 The majority of DCs in advanced plaques seems to be activated, as revealed by the expression of costimulatory molecules (eg, CD83 and CD86) and cytokines, and to cluster with T cells. 23 Figure. Dendritic cells (DCs) in atherosclerosis. CD11c + DCs can be found in atherosclerotic lesions, and exert different proatherogenic (black arrows) and protective functions (gray arrows) in disease development. DCs can engulf lipids to adopt a foam cell-like appearance (1) that may constitute the earliest stages of plaque formation. In addition, DCs regulate cholesterol homeostasis and decrease serum very low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) levels by yet unknown mechanisms (?) (2) . DCs can emigrate from atherosclerotic plaques in a CCR7-dependent manner (3) . DCs may also recruit T cells to the inflamed vessel wall via secretion of CCL17, CCL19, or CCL20 (4) . DCs in addition modulate T-cell responses (5): transforming growth factor (TGF)β type II receptor-signaling in DCs dampens proinflammatory T-cell activity in atherosclerosis. The TLR adaptor MyD88 in DCs is required for Treg-mediated suppression of atherosclerosis. Functions of specific DC subsets (text boxes) have been dissected. Plasmacytoid DCs (pDCs) promote atherosclerosis by a major histocompatibility complex (MHC)II-dependent activation of Th1 cell responses and secretion of interferon (IFN)-α; a subset of CCL17-expressing CD11b + DCs restrains Treg responses and drives atherosclerosis; CD103
+ classical DCs promote Treg responses and protect from atherosclerosis.
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in advanced compared with early plaques. 16 Using the pDC markers BDCA-4 or BDCA-2 + , however, few pDCs were detected in stable or unstable plaques. 18, 20 DCs can furthermore be detected in the adventitia and in tertiary lymphoid organs (TLOs) that form in the adventitia of aged Apoe −/− mice primarily in the proximal abdominal aorta. TLOs are organized into distinct compartments, including T-and B-cell areas, and harbor cDCs, pDCs, and monocytederived DCs. These TLOs may participate in primary immune responses in advanced atherosclerosis. 33 Of note, TLO-like adventitial aggregates are also reported in patients with atherosclerotic abdominal aneurysms, which may indicate a relevance of TLO formation also in humans. The mechanisms of their formation and function, as well as their location in humans are unknown and deserve attention in future studies. 33 Given recent advances in defining bone fide DCs, an in-depth characterization of the ontogeny of vascular and adventitial DCs in healthy and atherosclerotic arteries is now warranted. For example, fate mapping studies will bring clarity to the origin of vascular DCs versus macrophages, such as the one exploiting DNGR-1 expression 6 to trace cDC precursors. Subsequently, their transcriptional profiling could help identifying genes specifically regulated during disease development. This knowledge is requisite for further characterizing the phenotype and function of distinct DC subsets in atherosclerosis.
Trafficking of DCs
In mice, the 3 major DC precursors in blood include Flt3 + preDCs and pDCs, and macrophage colony-stimulating factor + monocytes. The loss of CD103 + and of some CD11b + cDCs in the nonatherosclerotic aorta in Flt3/Flt3l-deficient mice 4, 14 indicates that monocyte-derived DCs and bone fide cDCs are already present prior disease development. Whereas blood monocytes systemically increase, 34 it is unclear whether circulating DCs or their precursors are altered in hyperlipidemia. Importantly, however, DC numbers rapidly expand during atherosclerotic lesion growth, and a reduction in CD103 + cDCs and monocyte-derived DCs is evidenced in atherosclerotic arteries of mice lacking Flt3 and macrophage colony-stimulating factor, respectively. 4 A decrease in CD11c + DC numbers in Cx3cr1 −/− mice may relate to diminished DC or monocyte recruitment. 35 These data suggest that DCs or their precursors are recruited during disease development.
Elucidating the DC subsets/precursors in blood and other organs during atherogenesis may contribute to resolve the question of the origin of vascular DCs and could facilitate the identification of factors that regulate circulating and plaque DC numbers. Blocking the recruitment of specific DC subsets/ precursors may be tested as therapeutic approaches to limit lesion size and local inflammation. Notably, CD11c + MHCII + DCs can also proliferate in early lesions. 36 The contribution of DC (precursor) recruitment versus local proliferation remains to be defined.
Circulating DCs: Biomarkers of Disease?
In humans, several contradictory studies have addressed whether circulating DC numbers correlate with disease severity and thus may serve as biomarkers of disease. Shi et al 22 MHCII-specific T-cell activation 16, 19 Type I interferon production 16 CAD indicates coronary artery disease; cDC, classical DC; CDP, common DC precursor; DC, dendritic cell; Flt3, factor fms-like tyrosine kinase 3; M-CSFR, macrophage colony-stimulating factor receptor; MDP, monocyte-DC precursor; MHC, major histocompatibility complex; pDC, plasmacytoid DC; and ?, under debate. 27 The mechanisms responsible for the decline in blood DCs in atherosclerosis may include an enhanced recruitment to lymphoid organs or sites of inflammation, as suggested by their accumulation in vulnerable lesions, 20 an increased DC turnover, or a decreased production or release from bone marrow. 37 Interestingly, decreased numbers of blood Lin −
HLA-DR +

CD11c
+ cDCs and CD123 + pDCs in CAD correlated with decreased plasma FLt3L, suggesting that reduced DC counts in CAD may, in part, be because of an impaired DC differentiation from progenitors. 38 Although these studies have failed to unequivocally identify certain DC subsets as biomarkers of disease, the majority of studies observed a decline in DC numbers in CAD. With a finer delineation of circulating DC subsets/precursors, including CD141
+ cDCs, their abundance may proof to be useful as potential biomarkers of disease.
Emigration of DCs
The ability to migrate to secondary (or tertiary) lymphatic tissue is considered a functional characteristic of DCs. Although it is unclear where T-cell sensitization occurs, DCs may emigrate from the vessel wall after antigen uptake and home to lymphatic tissue. Indeed, CD11c + cells seem to be able to leave atherosclerotic plaques in a chemokine-dependent manner. When the aortic arch of Apoe −/− mice with established atherosclerotic lesions was transplanted into wild-type recipients, blockade of the CCR7 ligands CCL19 and CCL21 inhibited plaque regression and preserved CD11c + cell content, 39 suggesting that CCR7 mediates the egress of DCs during lesion regression. In other different models of lesion regression, however, deficiency of CCR7 did not affect myeloid cell content, and lead to increased lesion formation in Apoe −/− but reduced plaque development in Ldlr −/− mice, findings that may also relate to altered T-cell trafficking. 40 Whether DC emigration plays a role during atherogenesis remains to be defined, but may be impaired by a reduced migratory ability of DCs under conditions of hyperlipidemia.
41
DCs Take Up Lipids and Control Cholesterol Homeostasis
In the arterial intima, lipid accumulations can be found within vascular CD11c + DCs in Ldlr −/− mice after only few days of hypercholesterolemia, where they adopt a foam cell-like appearance that may constitute the earliest stages of plaque formation. 42 Several studies furthermore point toward a role of DCs in cholesterol metabolism. In mice overexpressing antiapoptotic Decreased in blood in CAD [24] [25] [26] [27] [28] Increased in unstable lesions 20, 29 Decreased in blood in CAD [25] [26] [27] [28] Present in atherosclerotic lesions 16, 30 Increased in unstable lesions 16, 30 Inflammatory amplifiers/ upregulation of TLR4 on cDCs/cytotoxic CD4 + T cells responses 30, 31 CAD indicates coronary artery disease; cDC, classical DC; DC, dendritic cell; Flt3, factor fms-like tyrosine kinase 3; MHC, major histocompatibility complex; and pDC, plasmacytoid DC. 
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hBcl-2 under the control of the CD11c promoter, the extended lifespan of DCs not only enhanced T-cell activation but also lead to hypocholesterolemia with a decrease in very low-density lipoprotein and LDL levels, resulting in a net unaltered lesion formation. 43 In the reverse approach, depletion of DCs in CD11c-DTR Apoe −/− mice induced an elevation in plasma cholesterol levels. 43 The mechanisms that underlie these effects remain to be addressed. Gautier et al 43 4 Lipid uptake may be mediated by scavenger receptors of modified LDL (eg, CD36) and be controlled by ABCA1/ ABCG1-mediated cholesterol efflux pathways, reverse cholesterol transport, activity of peroxisome proliferator-activated receptor-γ, or liver X receptors, as recently reviewed in macrophages 15 ; in addition, fluid-phase endocytosis of native or modified LDL by DCs may contribute to lipid uptake. 15 In future studies, these hypotheses will have to be experimentally tested. Especially in humans, a correlation between lipid levels and circulating or plaque DC numbers remains to be investigated. In addition, it will be interesting to characterize DC numbers and phenotype both in lesions and the circulation with regard to the expression of mediators that could control cholesterol metabolism in mice and humans. Enhancing the lipid-lowering potential of DCs could be an interesting approach to limit hypercholesterolemia and atherosclerosis.
DCs as Antigen Presenting Cells That Control T-Cell Activation and Phenotype
As discussed, DCs may emigrate from the vessel wall to home to lymphatic tissue, or interact with T cells in the adventitia. It may also be conceivable that circulating antigens can directly be ingested by DCs in the spleen or lymph node and that DCs at these sites contribute to T-cell priming. The presence of oligoclonally expanded T cells and CD4 + T cells reactive to disease-related antigens in human lesions indicates that priming of T cells or re-encounter of antigen may (also) occur locally at sites of inflammation in human atherosclerosis.
1,2
Classical DCs
In principle, vascular DCs bear the capacity to interact with T cells. In model systems, CD11c + MHCII + DCs take up injected antigen from the bloodstream, and after sorting are capable of inducing antigen-specific MHCI or MHCII-restricted T-cell proliferation in vitro. 45, 46 Furthermore, aortic DCs promote tumor necrosis factor-α and interferon (IFN)-γ production in exogenously added antigen-specific T cells from Apoe −/− mice ex vivo, 5 suggesting that DCs can cause local T-cell activation and proinflammatory cytokine production.
Several lines of evidence indicate that DC-T cell interactions causally contribute to atherogenesis. For instance, Ldlr −/− mice lacking the invariant chain of MHCII are protected from atherogenesis, caused by reduced T-cell activation in atheromata. 47 Evidence for DC-intrinsic effector functions in atherosclerosis was, furthermore, obtained by disrupting TGF-β type II receptor-signaling in CD11c + cells in Apoe −/− mice, which lead to increased atherosclerotic lesion formation and an expansion of activated effector/memory T cells, indicating that TGF-β-signaling in DCs dampens proinflammatory T-cell responses in atherosclerosis. 48 + cDC content, diminished systemic and local Treg numbers and increased atherosclerosis. 4 Moreover, the absence of the key TLR adaptor MyD88 in CD11c + DCs led to a loss in Tregs, which trumpeted decreased proatherogenic effector T-cell activation, and entailed an increased atherosclerotic lesion formation, indicating that Treg-mediated suppression of atherosclerosis requires MyD88 signaling in DCs. 49 Thus, specialized DC subsets exert pro-and anti-inflammatory functions in T-cell activation. Interestingly, reduced peripheral Treg numbers in patients with CAD 50 may be in line with an expansion of CCL17 + DCs in atherosclerosis and increased CCL17 serum levels in CAD, 51 or point toward a loss of tolerogenic DC subsets/functions in advanced atherosclerosis.
CCL17-expressing DCs also contribute to the accumulation of T cells in atherosclerotic lesions. 46 Moreover, adoptively transferred Ccr7 −/− T cells showed a reduced migration into the inflamed aorta; given the expression of CCR7 ligands CCL19/CCL21 by plaque DCs, DCs may also recruit or retain T cells in the inflamed vessel wall. 2, 40 In future studies, it will be important to further investigate the role of specific DC subsets and the effector molecules involved in modulating T-cell responses in atherosclerosis. Identifying genes expressed in certain DC subsets, for example, transcription factors differentially regulating DC subset development, may facilitate their specific targeting. For instance, harnessing the cDC-specific transcripton factor Zbtb46 3 may help to define the contribution of cDCs (versus monocytes/macrophages or pDCs) to adaptive immunity and atherosclerosis.
To link experimental observations to clinical manifestations of atherosclerosis, functions and associated DC effector molecules should be explored in human DCs from atherosclerotic plaques and blood, and correlated to disease severity. Targeting DC subsets or their mediators that drive atherosclerosis or enhance atheroprotective Treg responses could be of potential interest for translational therapeutic strategies.
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Plasmacytoid DCs
Several studies have addressed the role of pDCs in atherosclerosis. pDC-depletion using an antibody against BST2 (120G8) aggravated atherosclerotic lesion development in carotid arteries after collar placement and in aortic roots in diet-fed Ldlr −/− mice, attributed to a loss of IDO (indoleamine 2,3-dioxygenase)-dependent restraint in T-cell proliferation. 18 Contrary, pDC-depletion with a different antibody against BST2 (anti-PDCA-1) decreased diet-induced lesion formation in 2 independent studies in the aortic root and aorta in Apoe −/− mice. 16, 17 Self-DNA (eg, released from dying cells or in neutrophil extracellular traps) and an increased expression of the antimicrobial peptide Cramp/LL37 in atherosclerotic lesions was shown to stimulate breakdown of tolerance to self-DNA and promote IFN-α production by pDCs, aggravating early atherosclerosis and antidouble-stranded DNA antibody formation in Apoe −/− mice. 52 In addition to releasing type I interferons, pDCs however, also exert typical cDC functions. pDCs can present antigen via MHCII and stimulate T-cell activation, which is increased on oxidized LDL exposure, 16 and an increased antigen presentation was observed in aortic PDCA-1 + pDCs in atherosclerotic Apoe −/− mice, 17 suggesting that pDC-driven immunity is enhanced in atherosclerosis.
Notably, a recent study has now elegantly shown that genetically modified mice with a selective deficiency in pDCs (CD11c-restricted deletion of the transcription factor E2-2/ Tcf4) or an abrogation of MHCII-restricted antigen presentation by pDCs were protected from atherosclerotic lesion formation with a reduction in proatherogenic Th1 T cells. 19 Although pDCs may thus promote disease development by triggering IFN-α production, these studies provide compelling evidence for a critical role of MHCII-restricted antigen presentation by pDCs in driving proatherogenic T-cell responses in atherosclerosis.
In humans, CD123 + pDCs and their index cytokine IFN-α were suggested to function as inflammatory amplifiers. Secretion of IFN-α, triggered by stimulation of plaque tissue with CpGs in vitro, correlated with the expression of proinflammatory mediators (tumor necrosis factor-α, IFN-γ, and matrix metalloproteinase-9), upregulation of TLR4 on cDCs, and tumor necrosis factor-related apoptosis inducing ligand by CD4 + T cells, resulting in killing of vascular smooth muscle cells. 30, 31 Notably, isolated immune complexes containing DNA-fragments can stimulate IFN-α secretion by pDCs in vitro. 16, 52 Given findings that elevated antinuclear antibody titers are associated with a decreased carotid elasticity and can be found in patients with symptomatic compared with asymptomatic carotid artery stenosis, 16, 52 antinuclear antibodies may contribute to the pathogenic effect in atherosclerosis by activating pDCs.
It will now be interesting to further address the recruitment of pDCs and role of specific mediators in pDCs in atherosclerosis. Mouse models using strategies to investigate these factors, for example, in a CD11c and E2-2/Tcf4-restricted fashion, could be developed to further expand preclinical knowledge about this cell population in atherosclerosis. A possible function of pDCs in antigen presentation and T-cell stimulation in human atherosclerosis remains to be investigated.
The mechanisms of antigen uptake and activation, as well as the role of cytokines released by pDCs will be of importance to bring together existing data in humans and mice, and to move toward approaches to interfere with these processes for atheroprotection.
DC-Based Vaccination Approaches
Importantly, DC-based vaccination strategies have yielded encouraging results in animal models. For instance, oxidized LDL-pulsed bone marrow-derived DCs have been shown to induce oxidized LDL-specific T cells with a reduced Th1 profile, and to decrease atherosclerotic carotid artery plaque size in Ldlr −/− mice. 53 Moreover, tolerogenic bone marrow-derived DCs pulsed with the LDL protein ApoB100 in combination with IL-10 reduced effector T-cell proliferation, inhibited IFN-γ production, and increased the generation of Tregs, which was accompanied by a reduction in atherosclerotic lesion size in Ldlr −/− mice transgenic for human ApoB100. 54 These data indicate that DC-based therapeutic approaches harbor potential for the prevention of atherosclerosis. Although in these studies DCs were injected before the commencement of diet to induce atherosclerosis, further experiments are needed to test DC vaccination in mice with established disease. This is of particular importance as the feasibility of vaccination approaches at later stages of atherosclerosis may be prerequisite for an application in patients.
Conclusions
Distinct DC subsets can be found in arterial vessels in healthy mice and humans, and an accumulation of DCs is observed in atherosclerosis. Moreover, an increased abundance of DCs seems to correlate with signs of plaque vulnerability in humans.
Although there is tentative evidence that DCs control lipid uptake, cholesterol metabolism and modulate adaptive immune responses in atherosclerosis, a clear attribution to bona fide DCs and the exact molecular mechanisms engaged are mostly still unclear. Knowledge about the ontogeny of vascular DC subsets and of genes specifically expressed by these will be requisite to experimentally test and provide undisputed evidence of their role in atherosclerosis and of mediators that control recruitment, emigration, lipid uptake, and T-cell responses in mice. The relative scarcity of human tissue, with the exception of blood, has hampered translational efforts of mechanistic findings uncovered in mice. However, blood and human plaque tissue should be used to isolate specific DC subsets for these endeavors. The identification of human homologs of mouse DC subsets and further work in this area will aid to promote translational approaches.
A clear understanding of the functional contribution of DC subsets in atherosclerosis will serve as an essential basis for targeting proatherogenic or tolerogenic cell populations or their mediators as novel therapeutic approaches for treating cardiovascular disease.
